genae Buys e-novex

ANTWERP, Belgium --

genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced today the acquisition of e-novex, a leading provider of electronic data tools that change medical research.

e-novex' proprietary Electronic Data Capture (EDC) technology is widely adopted by pharmaceutical, biotech and medical device companies, CRO's, Academic Research Organizations (ARO) and individual researchers. The portfolio comprises of for approval studies and the disruptive technology edc2go which allows building an electronic Case Report Form (eCRF) in a matter of hours instead of weeks or months. The core lab tracker platform facilitates the management and tracking of image logistics and enables secure transfer of large image data sets.

"The purchase of e-novex further increases genae's capacity to provide electronic solutions to our customers in the medical industries. The acquisition is also expected to result in greater eHealth efficiencies and in significantly increasing our capabilities in data management and risk based monitoring," said Bart Segers, CEO of genae.

The entire e-novex staff will be integrated in genae's e-Solutions business unit that already includes data management and statistics efficiencies. There will be no disruptions of e-novex' services during the integration which will take place over the next three months.

For further information, please visit and

About the genae group

genae is involved in the development and commercialization of medical devices, biologics and therapies that change medical practice. As a full service CRO and innovative services provider for the medical industries, genae aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for clinical trial management, data management, statistical analysis, safety, regulatory, core laboratory and medical writing services for the medical industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium and is part of the genae group, the medical device CRO.

genae associates nv
Bart Segers, CEO
Justitiestraat 6B, 2018 Antwerp, Belgium
[email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.